

# A Eden Evins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8172995/publications.pdf>

Version: 2024-02-01

132  
papers

8,297  
citations

50276

46  
h-index

48315

88  
g-index

134  
all docs

134  
docs citations

134  
times ranked

8546  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. <i>Lancet, The</i> , 2016, 387, 2507-2520.	13.7	929
2	Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review. <i>JAMA Psychiatry</i> , 2016, 73, 292.	11.0	621
3	The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach. <i>Psychotherapy and Psychosomatics</i> , 2003, 72, 115-127.	8.8	407
4	Brain Reactivity to Smoking Cues Prior to Smoking Cessation Predicts Ability to Maintain Tobacco Abstinence. <i>Biological Psychiatry</i> , 2010, 67, 722-729.	1.3	371
5	Medical Morbidity and Mortality in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 183-194.	2.2	276
6	Single dose of a dopamine agonist impairs reinforcement learning in humans: Behavioral evidence from a laboratory-based measure of reward responsiveness. <i>Psychopharmacology</i> , 2008, 196, 221-232.	3.1	217
7	The Effects of Transdermal Nicotine on Cognition in Nonsmokers with Schizophrenia and Nonpsychiatric Controls. <i>Neuropsychopharmacology</i> , 2008, 33, 480-490.	5.4	217
8	Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1116-1121.	2.2	183
9	Maintenance Treatment With Varenicline for Smoking Cessation in Patients With Schizophrenia and Bipolar Disorder. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 145.	7.4	180
10	A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. <i>Nicotine and Tobacco Research</i> , 2001, 3, 397-403.	2.6	179
11	A Double-blind Placebo-Controlled Trial of Bupropion Sustained-Release for Smoking Cessation in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 218-225.	1.4	176
12	A 12-Week Double-Blind, Placebo-Controlled Study of Bupropion SR Added to High-Dose Dual Nicotine Replacement Therapy for Smoking Cessation or Reduction in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 380-386.	1.4	159
13	Cortical Thickness Abnormalities in Cocaine Addiction—A Reflection of Both Drug Use and a Pre-existing Disposition to Drug Abuse?. <i>Neuron</i> , 2008, 60, 174-188.	8.1	150
14	A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain. <i>American Journal of Psychiatry</i> , 2005, 162, 954-962.	7.2	136
15	Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, e5-e31.	5.6	133
16	Folate, Homocysteine, and Negative Symptoms in Schizophrenia. <i>American Journal of Psychiatry</i> , 2004, 161, 1705-1708.	7.2	127
17	Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study. <i>Schizophrenia Research</i> , 2008, 106, 320-327.	2.0	126
18	Neural Substrates of Attentional Bias for Smoking-Related Cues: An fMRI Study. <i>Neuropsychopharmacology</i> , 2010, 35, 2339-2345.	5.4	122

#	ARTICLE	IF	CITATIONS
19	Attitudes of Schizophrenia Outpatients Toward Psychiatric Medications. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1372-1376.	2.2	119
20	Single dose of a dopamine agonist impairs reinforcement learning in humans: Evidence from event-related potentials and computational modeling of striatal-cortical function. <i>Human Brain Mapping</i> , 2009, 30, 1963-1976.	3.6	117
21	Dietary Intake Profile of Patients with Schizophrenia. <i>Annals of Clinical Psychiatry</i> , 2006, 18, 99-105.	0.6	111
22	A Single Dose of Nicotine Enhances Reward Responsiveness in Nonsmokers: Implications for Development of Dependence. <i>Biological Psychiatry</i> , 2008, 63, 1061-1065.	1.3	111
23	d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. <i>Schizophrenia Research</i> , 2002, 56, 19-23.	2.0	109
24	Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. <i>Psychopharmacology</i> , 2008, 199, 89-98.	3.1	107
25	Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. <i>Biological Psychiatry</i> , 2002, 51, 493-497.	1.3	104
26	A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. <i>Psychopharmacology</i> , 2005, 179, 144-150.	3.1	103
27	Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. <i>Addiction</i> , 2016, 111, 599-612.	3.3	92
28	Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 165-169.	1.4	79
29	Two-Year Follow-Up of a Smoking Cessation Trial in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 307-311.	2.2	79
30	Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations. <i>CNS Drugs</i> , 2017, 31, 471-481.	5.9	76
31	Treatment of Tobacco Use Disorders in Smokers with Serious Mental Illness. <i>Harvard Review of Psychiatry</i> , 2015, 23, 90-98.	2.1	74
32	Inositol augmentation of lithium or valproate for bipolar depression. <i>Bipolar Disorders</i> , 2006, 8, 168-174.	1.9	69
33	High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. <i>Schizophrenia Research</i> , 2008, 102, 88-95.	2.0	69
34	Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. <i>Psychopharmacology</i> , 2005, 181, 358-363.	3.1	67
35	Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 108-116.	1.4	67
36	A placebo-controlled study of sildenafil effects on cognition in schizophrenia. <i>Psychopharmacology</i> , 2009, 202, 411-417.	3.1	65

#	ARTICLE	IF	CITATIONS
37	Sexual functioning, psychopathology and quality of life in patients with schizophrenia. Schizophrenia Research, 2007, 94, 119-127.	2.0	60
38	A Controlled Trial of Bupropion Added to Nicotine Patch and Behavioral Therapy for Smoking Cessation in Adults With Unipolar Depressive Disorders. Journal of Clinical Psychopharmacology, 2008, 28, 660-666.	1.4	59
39	Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. Addiction, 2018, 113, 1507-1516.	3.3	58
40	Effect of a Comprehensive Cardiovascular Risk Reduction Intervention in Persons With Serious Mental Illness. JAMA Network Open, 2020, 3, e207247.	5.9	58
41	Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence.. Experimental and Clinical Psychopharmacology, 2009, 17, 365-373.	1.8	57
42	Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions. Biological Psychiatry, 2016, 80, 274-283.	1.3	55
43	Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary, 2014, 17, 150-156.	2.9	53
44	Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed. Neuropsychopharmacology, 2016, 41, 393-401.	5.4	53
45	Independent Effects of Tobacco Abstinence and Bupropion on Cognitive Function in Schizophrenia. Journal of Clinical Psychiatry, 2005, 66, 1184-1190.	2.2	52
46	Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. Psychiatry Research, 2008, 159, 140-146.	3.3	49
47	Glucose Metabolism in Patients With Schizophrenia Treated With Olanzapine or Quetiapine. Journal of Clinical Psychiatry, 2006, 67, 789-797.	2.2	48
48	Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. Drug and Alcohol Dependence, 2012, 120, 7-13.	3.2	45
49	Predictors of Early Abstinence in Smokers With Schizophrenia. Journal of Clinical Psychiatry, 2008, 69, 1743-1750.	2.2	43
50	Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Research, 2010, 176, 99-102.	3.3	42
51	Lower gray matter density and functional connectivity in the anterior insula in smokers compared with never smokers. Addiction Biology, 2016, 21, 972-981.	2.6	42
52	A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. Bipolar Disorders, 2006, 8, 75-80.	1.9	41
53	Early onset marijuana use is associated with learning inefficiencies.. Neuropsychology, 2016, 30, 405-415.	1.3	41
54	Adjunctive Antidepressant Drug Therapies in the Treatment of Negative Symptoms of Schizophrenia. CNS Drugs, 1996, 6, 130-147.	5.9	39

#	ARTICLE	IF	CITATIONS
55	A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 457-465.	4.5	38
56	Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. <i>Psychopharmacology</i> , 2012, 219, 25-34.	3.1	38
57	Single dose propranolol does not affect physiologic or emotional reactivity to smoking cues. <i>Psychopharmacology</i> , 2015, 232, 1619-1628.	3.1	38
58	Clozapine-Associated Reduction in Arrest Rates of Psychotic Patients With Criminal Histories. <i>American Journal of Psychiatry</i> , 2001, 158, 270-274.	7.2	36
59	A Randomized, Double-Blind, Placebo-Controlled Trial of Long-Acting Risperidone in Cocaine-Dependent Men. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 480-486.	2.2	35
60	Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults. <i>JAMA Network Open</i> , 2022, 5, e222106.	5.9	34
61	Young adult cannabis users report greater propensity for risk-taking only in non-monetary domains. <i>Drug and Alcohol Dependence</i> , 2015, 147, 26-31.	3.2	31
62	Impulsive Social Influence Increases Impulsive Choices on a Temporal Discounting Task in Young Adults. <i>PLoS ONE</i> , 2014, 9, e101570.	2.5	31
63	Online recovery support meetings can help mitigate the public health consequences of COVID-19 for individuals with substance use disorder. <i>Addictive Behaviors</i> , 2021, 113, 106661.	3.0	27
64	The Effect of Marijuana Use on the Risk for Schizophrenia [CME]. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1463-1468.	2.2	26
65	Systematic review and meta-analysis of opioid antagonists for smoking cessation. <i>BMJ Open</i> , 2014, 4, e004393.	1.9	26
66	Efficacy and Safety of Pharmacotherapeutic Smoking Cessation Aids in Schizophrenia Spectrum Disorders: Subgroup Analysis of EAGLES. <i>Psychiatric Services</i> , 2021, 72, 7-15.	2.0	25
67	Oral glycine administration increases brain glycine/creatine ratios in men: A proton magnetic resonance spectroscopy study. <i>Psychiatry Research - Neuroimaging</i> , 2009, 173, 143-149.	1.8	24
68	Reward Responsiveness Varies by Smoking Status in Women with a History of Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2015, 40, 1940-1946.	5.4	24
69	Anterior cingulate proton spectroscopy glutamate levels differ as a function of smoking cessation outcome. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1709-1713.	4.8	23
70	Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia. <i>Psychopharmacology</i> , 2014, 231, 765-775.	3.1	23
71	A contingency management method for 30-days abstinence in non-treatment seeking young adult cannabis users. <i>Drug and Alcohol Dependence</i> , 2016, 167, 199-206.	3.2	23
72	Resting-State Brain Connectivity Predicts Weight Loss and Cognitive Control of Eating Behavior After Vertical Sleeve Gastrectomy. <i>Obesity</i> , 2019, 27, 1846-1855.	3.0	22

#	ARTICLE	IF	CITATIONS
73	Anterior insula activation during inhibition to smoking cues is associated with ability to maintain tobacco abstinence. Addictive Behaviors Reports, 2018, 7, 40-46.	1.9	21
74	Effective Cessation Strategies for Smokers with Schizophrenia. International Review of Neurobiology, 2015, 124, 133-147.	2.0	20
75	Neural mechanisms of sensitivity to peer information in young adult cannabis users. Cognitive, Affective and Behavioral Neuroscience, 2016, 16, 646-661.	2.0	20
76	Nicotine Increases Activation to Anticipatory Valence Cues in Anterior Insula and Striatum. Nicotine and Tobacco Research, 2018, 20, 851-858.	2.6	20
77	Validation of brief screening measures for depression and anxiety in young people with substance use disorders. Journal of Affective Disorders, 2021, 282, 1021-1029.	4.1	20
78	Waist Circumference is the Best Anthropometric Predictor for Insulin Resistance in Nondiabetic Patients with Schizophrenia Treated with Clozapine but not Olanzapine. Journal of Psychiatric Practice, 2009, 15, 251-261.	0.7	19
79	Finding the Right Match: Mindfulness Training May Potentiate the Therapeutic Effect of Nonjudgment of Inner Experience on Smoking Cessation. Substance Use and Misuse, 2014, 49, 586-594.	1.4	18
80	Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. Acta Psychiatrica Scandinavica, 2006, 113, 121-125.	4.5	17
81	Reassessing the Safety of Varenicline. American Journal of Psychiatry, 2013, 170, 1385-1387.	7.2	16
82	Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: Subgroup analysis of a randomized clinical trial. Journal of Affective Disorders, 2019, 256, 267-277.	4.1	16
83	Need for Cardiovascular Risk Reduction in Persons With Serious Mental Illness: Design of a Comprehensive Intervention. Frontiers in Psychiatry, 2018, 9, 786.	2.6	16
84	Smoking Cessation in Patients With Psychiatric Disorders. Primary Care Companion To the Journal of Clinical Psychiatry, 2008, 10, 52-58.	0.6	16
85	Case 39-2004. New England Journal of Medicine, 2004, 351, 2741-2749.	27.0	15
86	Maintenance pharmacotherapy normalizes the relapse curve in recently abstinent tobacco smokers with schizophrenia and bipolar disorder. Schizophrenia Research, 2017, 183, 124-129.	2.0	15
87	Improved Depressive Symptoms in Adults with Schizophrenia During a Smoking Cessation Attempt with Varenicline and Behavioral Therapy. Journal of Dual Diagnosis, 2017, 13, 168-178.	1.2	15
88	Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial. Journal of General Internal Medicine, 2019, 34, 862-870.	2.6	15
89	Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: Subgroup analysis of the randomized, active- and placebo-controlled EAGLES trial. Depression and Anxiety, 2020, 37, 247-260.	4.1	14
90	A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders: trial design and protocol. BMC Public Health, 2017, 17, 100.	2.9	13

#	ARTICLE	IF	CITATIONS
91	Prolonged cannabis withdrawal in young adults with lifetime psychiatric illness. <i>Preventive Medicine</i> , 2017, 104, 40-45.	3.4	13
92	A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking in Females. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 597-602.	1.4	11
93	Altered Neural Processing to Social Exclusion in Young Adult Marijuana Users. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2016, 1, 152-159.	1.5	11
94	Predictors of tobacco abstinence in outpatient smokers with schizophrenia or bipolar disorder treated with varenicline and cognitive behavioral smoking cessation therapy. <i>Addictive Behaviors</i> , 2017, 71, 89-95.	3.0	11
95	Using Functional Near-Infrared Spectroscopy to Measure Effects of Delta 9-Tetrahydrocannabinol on Prefrontal Activity and Working Memory in Cannabis Users. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 488.	2.0	11
96	Nicotine-induced activation of caudate and anterior cingulate cortex in response to errors in schizophrenia. <i>Psychopharmacology</i> , 2018, 235, 789-802.	3.1	10
97	Delta-9-tetrahydrocannabinol intoxication is associated with increased prefrontal activation as assessed with functional near-infrared spectroscopy: A report of a potential biomarker of intoxication. <i>NeuroImage</i> , 2019, 197, 575-585.	4.2	10
98	Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence. <i>Journal of Psychopharmacology</i> , 2020, 34, 197-210.	4.0	10
99	Effect of Social Influence on Effort-Allocation for Monetary Rewards. <i>PLoS ONE</i> , 2015, 10, e0126656.	2.5	9
100	A placebo-controlled randomized trial of D-cycloserine augmentation of cue exposure therapy for smoking cessation. <i>Cognitive Behaviour Therapy</i> , 2019, 48, 65-76.	3.5	9
101	Characteristics of Adult Cigarette Smokers Who “Relight” and the Effects of Exposure to Tobacco Smoke Constituents. <i>Nicotine and Tobacco Research</i> , 2019, 21, 1206-1212.	2.6	9
102	Acceptability of SPECTRUM Research Cigarettes among Participants in Trials of Reduced Nicotine Content Cigarettes. <i>Tobacco Regulatory Science (discontinued)</i> , 2018, 4, 573-585.	0.2	9
103	Smoking Cessation in Patients With Psychiatric Disorders. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1404-1410.	2.2	9
104	Does Using Marijuana Increase the Risk for Developing Schizophrenia?. <i>Journal of Clinical Psychiatry</i> , 2013, 74, e08.	2.2	8
105	Detecting treatment-covariate interactions using permutation methods. <i>Statistics in Medicine</i> , 2015, 34, 2035-2047.	1.6	7
106	Phase IIb Trial of an $\pm 7$ Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 307-316.	1.4	7
107	Cross-domain correlates of cannabis use disorder severity among young adults. <i>Addictive Behaviors</i> , 2019, 93, 212-218.	3.0	7
108	Reducing the Nicotine Content of Cigarettes: Effects in Smokers With Mental Health Conditions and Socioeconomic Disadvantages. <i>Nicotine and Tobacco Research</i> , 2019, 21, S26-S28.	2.6	7



#	ARTICLE	IF	CITATIONS
109	Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors. <i>Addiction</i> , 2021, 116, 2816-2824.	3.3	7
110	Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 8, 9-14.	2.2	7
111	Alcohol substitution during one month of cannabis abstinence among non-treatment seeking youth. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 107, 110205.	4.8	6
112	Assessing Changes in Symptoms of Depression and Anxiety During Four Weeks of Cannabis Abstinence Among Adolescents. <i>Frontiers in Psychiatry</i> , 2021, 12, 689957.	2.6	6
113	Sex Differences in Neuropsychological Functioning are Domain-Specific in Adolescent and Young Adult Regular Cannabis Users. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 592-606.	1.8	6
114	White matter integrity differences associated with post-traumatic stress disorder are not normalized by concurrent marijuana use. <i>Psychiatry Research - Neuroimaging</i> , 2020, 295, 111017.	1.8	4
115	Variation in Cannabinoid Metabolites Present in the Urine of Adults Using Medical Cannabis Products in Massachusetts. <i>JAMA Network Open</i> , 2021, 4, e215490.	5.9	4
116	Polygenic score for cigarette smoking is associated with ever electronic cigarette use in a college-aged sample. <i>Addiction</i> , 2022, 117, 1071-1078.	3.3	4
117	A Call to Action for Treatment of Comorbid Tobacco and Alcohol Dependence. <i>JAMA Psychiatry</i> , 2018, 75, 121.	11.0	3
118	Smoking cessation in people with serious mental illness. <i>Lancet Psychiatry</i> , 2019, 6, 563-564.	7.4	3
119	Virtual Group Therapy Programs—The Wave of the Future. <i>Journal of Adolescent Health</i> , 2021, 69, 527.	2.5	3
120	Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia. <i>Evidence-Based Mental Health</i> , 2010, 13, 120-120.	4.5	3
121	Performance Metrics of Substance Use Disorder Care Among Medicaid Enrollees in New York, New York. <i>JAMA Health Forum</i> , 2022, 3, e221771.	2.2	3
122	T. Kishi and N. Iwata: Varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 269-270.	3.2	2
123	T266. Memory Deficits are Reversible With Sustained Cannabis Abstinence Among Cannabis Using Adolescents. <i>Biological Psychiatry</i> , 2018, 83, S233.	1.3	2
124	Effects of various antipsychotics on driving-related cognitive performance in adults with schizophrenia. <i>Journal of Psychiatric Research</i> , 2020, 131, 152-159.	3.1	2
125	Developing a Sound Body: Open Trial Results of a Group Healthy Lifestyle Intervention for Young Adults with Psychosis. <i>Community Mental Health Journal</i> , 2021, 57, 864-871.	2.0	2
126	Patient Experience and Predictors of Improvement in a Group Behavioral and Educational Intervention for Individuals With Diabetes and Serious Mental Illness: Mixed Methods Case Study. <i>Journal of Participatory Medicine</i> , 2021, 13, e21934.	1.3	2



#	ARTICLE	IF	CITATIONS
127	Randomised, pragmatic, waitlist controlled trial of cannabis added to prescription opioid support on opioid dose reduction and pain in adults with chronic non-cancer pain: study protocol. BMJ Open, 2022, 12, e064457.	1.9	2
128	Possible role of nicotine for the treatment of mild cognitive impairment. Expert Review of Neurotherapeutics, 2012, 12, 531-533.	2.8	1
129	Effect of Cigarette Rod Length on Smokers Switching to SPECTRUM Cigarettes. American Journal of Health Behavior, 2019, 43, 380-392.	1.4	1
130	Integrated Smoking Cessation for Smokers With Serious Mental Illness: Protocol for a Convergent Mixed Methods Implementation Evaluation Study. JMIR Research Protocols, 2021, 10, e25390.	1.0	1
131	Implementing Chronic Care Model Treatments for Cigarette Dependence in Community Mental Health Clinics. Journal of Dual Diagnosis, 0, , 1-12.	1.2	1
132	Reply to Comments by Dr Babbar. Journal of Clinical Psychopharmacology, 2007, 27, 240.	1.4	0